Anti-GLG1 antibody

  • Description

  • Application Data


An antibody raised against E-selectin ligand-1 (ESL-1); also known as GLG1, it is a golgi apparatus-localized protein which acts in osteoblasts to regulate bone homeostasis.

See full description

Application Data

Catalogue number crb2005619
Antibody Anti-GLG1 antibody
Antigen Peptide KLH conjugated synthetic peptide crb1200815e
Protein ID Q92896 Human GLG1
Aliases Golgi apparatus protein 1, Cysteine-rich fibroblast growth factor receptor, CFR-1, E-selectin ligand 1, ESL-1, Golgi sialoglycoprotein MG-160, GLG1, CFR1, ESL1, MG160
Cross-Reactivity Human, Mouse, Rat
Host Species Rabbit
Antibody Type Polyclonal
Concentration 1mg/ml
Target GLG1
Post-translational Modification Fucosylation, N-glycosylated
Material Safety Data Sheet (MSDS)

ESL-1 as an important regulator of bone remodelling which localises to the Golgi apparatus. It functions to maintain a balanced bone homeostasis where it can play either a catabolic or anabolic role. ESL-1 regulates TGF-β maturation during cartilage homeostasis. ESL-1 is also a novel adiponectin (APN)-binding protein. APN is an adipocyte-derived bioactive molecule with anti-diabetic and anti-atherogenic properties. ESL-1 is also a novel polysialic acid (polySia) acceptor. PolySia is a protein-modifying glycan implicated in modulating microglia activity.

GLG1 acts in the initial process to tether leukocytes to vascular endothelium however, this role has been implicated in the method tumour cells are able to progress and migrate. GLG1 has also been linked to the Lou Gehrig’s disease also known as Amyotrophic Lateral Sclerosis 1 (ALS1).   

Anti-GLG1 antibody

Cat No.Pack SizePriceQty.
Bulk Quote